GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations (opens ClinicalTrials.gov)
- Sponsor
- University of Copenhagen
- Enrolment
- 50
- Started
- 2014-06
- Last update
- 2020-05-13
Conditions: Obesity
Interventions: Liraglutide
Research discovery
— registered studies
Verify this search on the official site ↗ · fetched Nov 5, 2026, 9:32 AM UTC
Status on this page
A registered trial is a plan, not a result. “Results posted” means the sponsor uploaded summary results to the registry; it says nothing about whether the treatment worked.
Conditions: Obesity
Interventions: Liraglutide
Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: Liraglutide, Placebo
Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: semaglutide, liraglutide, placebo
Conditions: Obesity, Type 2 Diabetes Mellitus
Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: Liraglutide 3.0 mg, Placebo
Conditions: Weight Loss
Interventions: Liraglutide 6 MG/ML, Placebos
Conditions: Obesity
Interventions: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin degludec/liraglutide, Insulin degludec
Conditions: Type 1 Diabetes Mellitus, Autoimmune Diabetes
Interventions: Liraglutide, Insulin
Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: liraglutide, placebo, CMS Intensive Behavior Therapy
Conditions: Type 2 Diabetes
Interventions: SGLT2 inhibitor, GLP-1 receptor agonist
Conditions: Type 1 Diabetes
Interventions: Liraglutide, Placebo
Conditions: Diabetes Mellitus, Type 2
Interventions: Automatic system guided treatment, Standard treatment
Conditions: Obesity
Interventions: JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3, Liraglutide…
Conditions: Type 2 Diabetes Mellitus
Interventions: OPTIFAST
Conditions: Type 2 Diabetes Mellitus, Cardiovascular Disease
Interventions: Liraglutide, Sitagliptin
Conditions: Type 1 Diabetes
Interventions: ePID closed loop system, liraglutide
Conditions: Type 2 Diabetes
Interventions: Liraglutide, Sulfonylurea or Pioglitazone, Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide
Conditions: Type 2 Diabetes Mellitus
Interventions: Canagliflozin, Liraglutide
Conditions: Type 1 Diabetes
Interventions: liraglutide, placebo